According to the European Society of Cardiology (ESC) 2023 guidelines, SGLT-2 inhibitors and/or GLP-1 receptor agonists are recommended for individuals with T2D and cardiovascular disorders [72]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.